Sudbury, MA – According to filings with the U.S. Securities and Exchange Commission, CytoSite BioPharma is raising $5,099,995.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Jenson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About CytoSite BioPharma

Cytosite Bio is developing precision imaging products that determine patient response to immuno-oncology therapy very early in the treatment cycle. Our products detect active Granzyme B, the primary element responsible for the killing of tumor cells by the immune system. Our products enable individually-optimized treatments for patients, and more rapid evaluation of new drugs and drug combinations, using non-invasive, whole-body PET imaging.

To learn more about CytoSite BioPharma, visit http://www.cytositebio.com/

Contact:
James Jenson, Chief Executive Officer
978-460-0695
https://www.linkedin.com/in/jamescraigjenson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved